Message Font: Serif | Sans-Serif
No. of Recommendations: 0

Boston Scientific (BSX:NYSE - news - research) said Monday that early sales of its Taxus drug-coated stent for heart disease patients have exceeded expectations.

The Natick, Mass.-based company said after the bell that the stent -- which is inserted into arteries to facilitate blood flow and reduce the risk of arterial clogging -- produced $98 million in U.S. sales between March 8 and March 31, according to preliminary results. Official results will be published in two weeks when the company issues its financial report for the quarter ended March 31.

Boston Scientific had predicted in late February that U.S. Taxus sales would be between $54 million and $75 million for the period March 1 to March 31. But the Food and Drug Administrationslightly delayed the company's plans because the agency approved the device on March 4.
Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.